ES2893749T3 - Derivados de fumagilol y polimorfos de los mismos - Google Patents
Derivados de fumagilol y polimorfos de los mismos Download PDFInfo
- Publication number
- ES2893749T3 ES2893749T3 ES16816157T ES16816157T ES2893749T3 ES 2893749 T3 ES2893749 T3 ES 2893749T3 ES 16816157 T ES16816157 T ES 16816157T ES 16816157 T ES16816157 T ES 16816157T ES 2893749 T3 ES2893749 T3 ES 2893749T3
- Authority
- ES
- Spain
- Prior art keywords
- aminocyclohexyl
- trans
- benzenesulfonic acid
- fumaryl
- acid salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 CCC(C)(C)CC(C)(C(C)C(C)(C(C)(C)C(C)(*)/C=*/*(N1)O)C1=O)C(NCC(C)C)=O Chemical compound CCC(C)(C)CC(C)(C(C)C(C)(C(C)(C)C(C)(*)/C=*/*(N1)O)C1=O)C(NCC(C)C)=O 0.000 description 5
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
- C07D303/02—Compounds containing oxirane rings
- C07D303/12—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms
- C07D303/18—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms by etherified hydroxyl radicals
- C07D303/31—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms by etherified hydroxyl radicals in which the oxirane rings are condensed with a carbocyclic ring system having three or more relevant rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C65/01—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups
- C07C65/105—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups polycyclic
- C07C65/11—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups polycyclic with carboxyl groups on a condensed ring system containing two rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
- C07D303/02—Compounds containing oxirane rings
- C07D303/38—Compounds containing oxirane rings with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D303/46—Compounds containing oxirane rings with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals by amide or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Epoxy Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562265675P | 2015-12-10 | 2015-12-10 | |
| PCT/US2016/065799 WO2017100553A1 (en) | 2015-12-10 | 2016-12-09 | Fumagillol derivatives and polymorphs thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2893749T3 true ES2893749T3 (es) | 2022-02-10 |
Family
ID=57589276
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES16816157T Active ES2893749T3 (es) | 2015-12-10 | 2016-12-09 | Derivados de fumagilol y polimorfos de los mismos |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US9969722B2 (enExample) |
| EP (1) | EP3386956B1 (enExample) |
| JP (2) | JP7553224B2 (enExample) |
| KR (2) | KR102849342B1 (enExample) |
| CN (1) | CN108290853B (enExample) |
| AU (1) | AU2016366306B2 (enExample) |
| CA (1) | CA3005450A1 (enExample) |
| DK (1) | DK3386956T3 (enExample) |
| ES (1) | ES2893749T3 (enExample) |
| MX (2) | MX2018006904A (enExample) |
| WO (1) | WO2017100553A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3858385B1 (en) | 2010-05-25 | 2024-09-11 | Syndevrx, Inc. | Polymer-conjugated metap2 inhibitors, and therapeutic methods of use thereof |
| MX371095B (es) | 2013-04-10 | 2020-01-16 | Syndevrx Inc | Inhibidores de metionina aminopeptidasa-2 y metodos de tratamiento de la obesidad. |
| CN108290853B (zh) * | 2015-12-10 | 2022-05-31 | 辛德弗雷克斯公司 | 烟曲霉醇衍生物及其多晶型物 |
| CA3008960C (en) | 2016-01-11 | 2024-07-02 | Syndevrx, Inc. | TREATMENT OF TUMORS INDUCED BY METABOLIC DYSFUNCTION |
| EP3870231A1 (en) | 2018-10-26 | 2021-09-01 | Syndevrx, Inc. | Biomarkers of metap2 inhibitors and applications thereof |
| WO2024040009A2 (en) * | 2022-08-17 | 2024-02-22 | Primetime Life Sciences, Llc | Inhibitors of methionine aminopeptidase-2 and methods of preparation and uses thereof |
Family Cites Families (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8500209D0 (en) | 1985-01-04 | 1985-02-13 | Ceskoslovenska Akademie Ved | Synthetic polymeric drugs |
| SE8702550D0 (sv) | 1987-06-18 | 1987-06-18 | Anders Grubb | Cysteinproteashemmare |
| US5166172A (en) | 1988-09-01 | 1992-11-24 | Takeda Chemical Industries, Ltd. | Fumagillol derivatives and pharmaceutical compositions thereof |
| US4997878A (en) | 1988-12-29 | 1991-03-05 | Exxon Research And Engineering Company | Hydrophobically associating polymers containing dimethyl acrylamide functionality |
| US5258453A (en) | 1992-01-21 | 1993-11-02 | University Of Utah | Drug delivery system for the simultaneous delivery of drugs activatable by enzymes and light |
| GB9320781D0 (en) | 1993-10-08 | 1993-12-01 | Erba Carlo Spa | Polymer-bound camptothecin derivatives |
| US20030220233A1 (en) | 1994-01-24 | 2003-11-27 | Neorx Corporation | Radiolabeled annexins |
| TW527183B (en) | 1996-06-06 | 2003-04-11 | Daiichi Seiyaku Co | Drug complex |
| TW409058B (en) | 1996-06-06 | 2000-10-21 | Daiichi Seiyaku Co | Method for preparation of a drug complex |
| US6759509B1 (en) | 1996-11-05 | 2004-07-06 | Bristol-Myers Squibb Company | Branched peptide linkers |
| AU9376998A (en) | 1997-09-02 | 1999-03-22 | Johns Hopkins University School Of Medicine, The | Vitamin d3 analog loaded polymer formulations for cancer and neurodegenerative disorders |
| AU3352799A (en) | 1997-10-31 | 1999-08-23 | Children's Medical Center Corporation | Method for regulating size and growth of vascularized normal tissue |
| KR100357542B1 (ko) | 1998-05-15 | 2002-10-18 | 주식회사종근당 | 푸마질롤 유도체 및 그 제조방법 |
| EA003398B1 (ru) | 1998-05-22 | 2003-04-24 | Дайити Фармасьютикал Ко., Лтд. | Лекарственный комплекс c полимерным носителем |
| US6464850B1 (en) | 1998-07-31 | 2002-10-15 | Biowhittaker Molecular Applications, Inc. | Method for producing hydrophilic monomers and uses thereof |
| EP1155702A4 (en) | 1998-10-30 | 2004-12-15 | Daiichi Seiyaku Co | DDS CONNECTIONS AND TEST METHODS |
| WO2001018080A1 (en) | 1999-09-08 | 2001-03-15 | School Of Pharmacy, University Of London | Uniform molecular weight polymers |
| US6811788B2 (en) | 2000-01-19 | 2004-11-02 | Baofa Yu | Combinations and methods for treating neoplasms |
| US6548477B1 (en) | 2000-11-01 | 2003-04-15 | Praecis Pharmaceuticals Inc. | Therapeutic agents and methods of use thereof for the modulation of angiogenesis |
| US20070161570A1 (en) | 2000-11-01 | 2007-07-12 | Praecis Pharmaceuticals, Inc. | Methionine aminopeptidase-2 inhibitors and methods of use thereof |
| EP1243276A1 (en) | 2001-03-23 | 2002-09-25 | Franciscus Marinus Hendrikus De Groot | Elongated and multiple spacers containing activatible prodrugs |
| US7091186B2 (en) | 2001-09-24 | 2006-08-15 | Seattle Genetics, Inc. | p-Amidobenzylethers in drug delivery agents |
| US7087768B2 (en) | 2001-09-27 | 2006-08-08 | Equispharm Co., Ltd. | Fumagillol derivatives and preparing method thereof |
| WO2003070173A2 (en) | 2002-02-15 | 2003-08-28 | Sympore Gmbh | Conjugates of biologically active compounds, methods for their preparation and use, formulation and pharmaceutical applications thereof |
| AU2003230852B2 (en) | 2002-04-11 | 2008-07-10 | Children's Medical Center Corporation | TNP-470 polymer conjugates and use thereof |
| US20040001801A1 (en) | 2002-05-23 | 2004-01-01 | Corvas International, Inc. | Conjugates activated by cell surface proteases and therapeutic uses thereof |
| US20040116348A1 (en) | 2002-09-23 | 2004-06-17 | Ying Chau | Polymer-linker-drug conjugates for targeted drug delivery |
| US20040228831A1 (en) | 2003-05-15 | 2004-11-18 | Belinka Benjamin A. | Polymeric conjugates for tissue activated drug delivery |
| JP4682152B2 (ja) | 2003-12-31 | 2011-05-11 | ザ・ペン・ステート・リサーチ・ファンデーション | 卵巣がんの化学療法に対する抵抗性を予測および克服するための方法ならびに結腸がんの発生を予測するための方法 |
| US20070287680A1 (en) | 2004-05-10 | 2007-12-13 | University Of Utah Research Foundation | Combined Active and Passive Targeting of Biologically Active Agents |
| US7214664B2 (en) | 2004-12-03 | 2007-05-08 | The Curators Of The University Of Missouri | Peptidyl prodrugs that resist P-glycoprotein mediated drug efflux |
| WO2006084054A2 (en) | 2005-02-02 | 2006-08-10 | Children's Medical Center Corporation | Method of treating angiogenic diseases |
| US7629315B2 (en) | 2005-03-09 | 2009-12-08 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Compositions for blocking the inhibitory effect of human CRP on human leptin |
| WO2006124711A1 (en) | 2005-05-16 | 2006-11-23 | The Board Of Trustees Of The University Of Illinois | Composition and method for providing localized delivery of a therapeutic agent |
| WO2009003110A2 (en) | 2007-06-26 | 2008-12-31 | Children's Medical Center Corporation | Metap-2 inhibitor polymersomes for therapeutic administration |
| WO2009036108A1 (en) | 2007-09-13 | 2009-03-19 | Children's Medical Center Corporation | Methods and compositions for inhibiting vascular leakage |
| US20090104210A1 (en) | 2007-10-17 | 2009-04-23 | Tota Michael R | Peptide compounds for treating obesity and insulin resistance |
| NZ585547A (en) | 2007-11-28 | 2012-12-21 | Mersana Therapeutics Inc | Biocompatible biodegradable fumagillin analog conjugates |
| US20100298371A1 (en) | 2007-12-04 | 2010-11-25 | Mayank Ghanshyambhai Dave | Process for preparing chemically and chirally pure solifenacin base and its salts |
| EP2244712B1 (en) | 2008-01-22 | 2015-08-05 | Thar Pharmaceuticals Inc. | In vivo studies of crystalline forms of meloxicam |
| CN102105156B (zh) | 2008-05-22 | 2016-05-25 | 特拉维夫大学拉莫特有限公司 | 连接有治疗活性剂和血管生成靶向部分的聚合物的新型缀合物及其在治疗血管生成相关疾病中的用途 |
| DE102008027574A1 (de) | 2008-06-10 | 2009-12-17 | Merck Patent Gmbh | Neue Pyrrolidinderivate als MetAP-2 Inhibitoren |
| WO2010065877A2 (en) | 2008-12-04 | 2010-06-10 | Zafgen Corporation | Methods of treating an overweight or obese subject |
| US8642650B2 (en) | 2008-12-04 | 2014-02-04 | Zafgen, Inc. | Methods of treating an overweight or obese subject |
| TWI373345B (en) | 2009-02-19 | 2012-10-01 | Academia Sinica | Breast cancer-targeting peptides and use thereof |
| EP2493497A4 (en) | 2009-11-01 | 2013-07-24 | Brigham & Womens Hospital | NOTCH INHIBITION IN THE TREATMENT AND PROPHYLAXIS OF ADIPOSITAS AND METABOLISM SYNDROME |
| WO2011127304A2 (en) | 2010-04-07 | 2011-10-13 | Zafgen Corporation | Methods of treating an overweight subject |
| US9895449B2 (en) | 2010-05-25 | 2018-02-20 | Syndevrx, Inc. | Polymer-conjugated MetAP2 inhibitors, and therapeutic methods of use thereof |
| EP3858385B1 (en) | 2010-05-25 | 2024-09-11 | Syndevrx, Inc. | Polymer-conjugated metap2 inhibitors, and therapeutic methods of use thereof |
| EP2575887A4 (en) | 2010-05-25 | 2015-01-14 | SynDevRX | CONJUGATES OF OPTIMIZED MEDICINES |
| PH12013500934A1 (en) | 2010-11-09 | 2022-10-24 | Zafgen Inc | Crystalline solids of a metap-2 inhibitor and methods of making and using same |
| JP5876513B2 (ja) | 2011-03-08 | 2016-03-02 | ザフゲン，インコーポレイテッド | オキサスピロ［２．５］オクタン誘導体および類似体 |
| US9573918B2 (en) * | 2012-05-09 | 2017-02-21 | Zafgen, Inc. | Fumigillol compounds and methods of making and using same |
| MX371095B (es) | 2013-04-10 | 2020-01-16 | Syndevrx Inc | Inhibidores de metionina aminopeptidasa-2 y metodos de tratamiento de la obesidad. |
| CN108290853B (zh) * | 2015-12-10 | 2022-05-31 | 辛德弗雷克斯公司 | 烟曲霉醇衍生物及其多晶型物 |
| CA3008960C (en) | 2016-01-11 | 2024-07-02 | Syndevrx, Inc. | TREATMENT OF TUMORS INDUCED BY METABOLIC DYSFUNCTION |
-
2016
- 2016-12-09 CN CN201680072272.XA patent/CN108290853B/zh active Active
- 2016-12-09 AU AU2016366306A patent/AU2016366306B2/en active Active
- 2016-12-09 DK DK16816157.8T patent/DK3386956T3/da active
- 2016-12-09 ES ES16816157T patent/ES2893749T3/es active Active
- 2016-12-09 MX MX2018006904A patent/MX2018006904A/es unknown
- 2016-12-09 JP JP2018529646A patent/JP7553224B2/ja active Active
- 2016-12-09 KR KR1020187019456A patent/KR102849342B1/ko active Active
- 2016-12-09 CA CA3005450A patent/CA3005450A1/en active Pending
- 2016-12-09 EP EP16816157.8A patent/EP3386956B1/en active Active
- 2016-12-09 KR KR1020257027526A patent/KR20250127347A/ko active Pending
- 2016-12-09 US US15/373,874 patent/US9969722B2/en active Active
- 2016-12-09 WO PCT/US2016/065799 patent/WO2017100553A1/en not_active Ceased
-
2018
- 2018-04-06 US US15/946,899 patent/US10287277B2/en active Active
- 2018-06-06 MX MX2023002589A patent/MX2023002589A/es unknown
-
2024
- 2024-05-02 JP JP2024074818A patent/JP2024103495A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MX2018006904A (es) | 2018-08-24 |
| AU2016366306A1 (en) | 2018-05-31 |
| CN108290853A (zh) | 2018-07-17 |
| HK1258254A1 (zh) | 2019-11-08 |
| EP3386956A1 (en) | 2018-10-17 |
| JP2024103495A (ja) | 2024-08-01 |
| KR20250127347A (ko) | 2025-08-26 |
| US20180291010A1 (en) | 2018-10-11 |
| CA3005450A1 (en) | 2017-06-15 |
| JP7553224B2 (ja) | 2024-09-18 |
| US10287277B2 (en) | 2019-05-14 |
| MX2023002589A (es) | 2023-03-22 |
| KR20180093995A (ko) | 2018-08-22 |
| WO2017100553A1 (en) | 2017-06-15 |
| US9969722B2 (en) | 2018-05-15 |
| US20170166556A1 (en) | 2017-06-15 |
| AU2016366306B2 (en) | 2021-02-25 |
| DK3386956T3 (da) | 2021-10-11 |
| KR102849342B1 (ko) | 2025-08-21 |
| JP2019501898A (ja) | 2019-01-24 |
| EP3386956B1 (en) | 2021-07-14 |
| CN108290853B (zh) | 2022-05-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2893749T3 (es) | Derivados de fumagilol y polimorfos de los mismos | |
| WO2021088938A1 (zh) | 四氢吡啶并嘧啶类抑制剂及其制备方法和应用 | |
| RU2686722C1 (ru) | Новые кристаллы урацильного соединения | |
| JP2019522051A (ja) | トリアゾロピリミジン化合物の結晶形態 | |
| CN104379582A (zh) | 包含达沙替尼和所选择的共晶体形成剂的多组分晶体 | |
| WO2016124137A1 (zh) | 一种表皮生长因子受体抑制剂的磷酸盐、其晶型及制备方法 | |
| ES2971258T3 (es) | Nuevas formas cristalinas de una tienopirimidina como inhibidor de MCL-1 | |
| TW201904954A (zh) | 一種苯并哌啶類衍生物的鹽、其晶型及鹽、其晶型的製備方法 | |
| ES2539236T3 (es) | Sal de ácido benzoico de Otamixaban | |
| US11136332B2 (en) | Morphic forms of marizomib and uses thereof | |
| US9266822B2 (en) | Solid forms of tacedinaline | |
| HK1258254B (en) | Fumagillol derivatives and polymorphs thereof | |
| US11787819B2 (en) | Crystalline salt of a multi-tyrosine kinase inhibitor, method of preparation, and use thereof | |
| US8575214B2 (en) | MGlu 2/3 agonists | |
| EP3812384B1 (en) | Maleate of benzothiophene compound, crystalline form thereof and use thereof | |
| BR122024009277A2 (pt) | Formas cristalinas de um composto de triazolopirimidina | |
| BR112018076443B1 (pt) | Processo de preparação de formas cristalinas de um composto de triazolopirimidina |